Want to see AU:BLS full AI Analyst Report?
Top Page
Bioxyne Limited
(Sydney:BLS)
Select Model
Select Model
Rating:78Outperform
Price Target:
AU$0.95
▲(2265.00% Upside)
Action:Reiterated
Date:06/24/26
The score is driven primarily by strong financial performance (rapid revenue growth, improved profitability, low leverage, and materially better cash flow) and supportive bullish technicals (price above key moving averages with positive MACD and healthy RSI). The main offset is valuation, with a P/E of 25 and no dividend yield data to bolster return potential.
Positive Factors
Strong revenue growth
Sustained high revenue growth indicates strong product uptake and expanding market penetration in regulated medicinal cannabis channels. Over 2-6 months this underpins reinvestment ability, supports scale economics, and helps justify further commercialization and regulatory investment to extend market access.
Negative Factors
Relatively low gross margin
A sub-40% gross margin constrains the company's ability to absorb input cost inflation and invest in R&D or market expansion while maintaining healthy net margins. Over several months this limits margin sustainability versus peers and necessitates operational or procurement improvements to improve long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained high revenue growth indicates strong product uptake and expanding market penetration in regulated medicinal cannabis channels. Over 2-6 months this underpins reinvestment ability, supports scale economics, and helps justify further commercialization and regulatory investment to extend market access.
Read all positive factors
Bioxyne Limited (BLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$185.57M
Dividend YieldN/A
Average Volume (3M)4.35M
Price to Earnings (P/E)23.1
Beta (1Y)1.52
Revenue Growth174.51%
EPS Growth265.77%
CountryAU
Employees16
SectorGeneral
Sector StrengthN/A
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)0.04
Shares Outstanding229,103,590
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$105.60M
Bioxyne Limited Business Overview & Revenue Model
Company Description
BLS Pharmaceuticals Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United State...
How the Company Makes Money
Bioxyne generates revenue primarily from medicinal cannabis-related activities, including (where permitted under applicable regulation) sales of cannabis products and/or cannabis-derived formulations, and fees or margins associated with distributi...
Bioxyne Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Bioxyne Limited Technical Analysis
Positive
0.04
Price Trends
0.89
Positive
0.78
Positive
0.60
Positive
Market Momentum
>-0.01
Negative
57.18
Neutral
78.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BLS, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.89, and below the 200-day MA of 0.60, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.18 is Neutral, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BLS.
Bioxyne Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$185.57M | 23.09 | 56.29% | ― | 174.51% | 265.77% | |
75 Outperform | AU$160.32M | 18.05 | 12.22% | 2.27% | 27.60% | 96.31% | |
56 Neutral | AU$76.00M | 20.24 | 8.70% | ― | 23.29% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | AU$7.33M | -0.01 | 226.76% | ― | -32.83% | 83.37% | |
42 Neutral | AU$29.43M | -30.77 | -321.20% | ― | 2.96% | -866.67% | |
40 Underperform | AU$13.33M | -2.78 | -41.69% | ― | 53.69% | 45.24% |
* General Sector Average
AU:BLS
Bioxyne Limited
0.91
0.40
78.43%
AU:BUB
Bubs Australia Ltd.
0.09
-0.07
-41.88%
AU:NUC
Nuchev Pty Ltd
0.09
-0.09
-51.43%
AU:HCT
Holista Colltech Limited
0.07
-0.03
-33.00%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
4.76%
AU:CLV
Clover Corporation Limited
0.96
0.41
74.23%
Bioxyne Limited Corporate Events
BLS Pharmaceuticals to Outline Growth Strategy at Coffee Microcaps Forum
Jul 30, 2026
BLS Pharmaceuticals Limited will present at the Coffee Microcaps Morning Meeting on 31 July 2026, where Executive Director and COO Jason Hine is set to outline the company’s June quarter results, recent operational milestones and its broader...
BLS Pharmaceuticals Updates Investors Ahead of Q4 FY2026 Results Webinar
Jul 29, 2026
BLS Pharmaceuticals Limited has released an updated investor presentation ahead of its Q4 FY2026 results webinar scheduled for 31 July 2026. The presentation and subsequent recording will provide investors with detailed insights into the company&#...
BLS Pharmaceuticals to Brief Investors on Q4 FY2026 Results in Upcoming Webinar
Jul 29, 2026
BLS Pharmaceuticals Limited will host an investor webinar on 31 July 2026 to discuss its June quarter FY2026 results, recent operational highlights and growth strategy. The session, led by CEO and Managing Director Sam Watson, will include a prese...
BLS Pharmaceuticals to Commercialise Trexapharm’s TREXAVIVE Neurotherapy in Australia
Jul 21, 2026
BLS Pharmaceuticals has entered a non-binding Heads of Agreement with Trexapharm to become the preferred commercial partner in Australia for TREXAVIVE, a proprietary neurotherapy targeting treatment-resistant depression and related disorders. The ...
BLS Pharmaceuticals Expands Global Psychedelic Medicines Reach via Cayman Partnership
Jul 21, 2026
BLS Pharmaceuticals has entered an international referral agreement with Cayman Chemical Company, under which Cayman will direct global customers seeking finished MDMA and psilocybin dosage forms to BLS. The deal, which complements an existing API...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.